Adjunctive brivaracetam and sustained seizure frequency reduction in very active focal epilepsy
Epilepsia · 2023-11 · 64 (11) · 2922-2933
DOI: 10.1111/epi.17740 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia, online erschienen am 09.09.2023. Verfasst von Simona Lattanzi und 25 weiteren Autor:innen. Beteiligte Einrichtung: Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsies, Partial. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
This study aimed to explore the effectiveness of brivaracetam (BRV) according to baseline seizure frequency and past treatment history in subjects with focal epilepsy who were included in the Brivaracetam Add‐On First Italian Network Study (BRIVAFIRST).
Methods
BRIVAFIRST was a 12‐month retrospective, multicenter study including adults prescribed adjunctive BRV. Study outcomes included sustained seizure response (SSR), sustained seizure freedom (SSF), and the rates of treatment discontinuation and adverse events (AEs). Baseline seizure frequency was stratified as 20 seizures per month, and the number of prior antiseizure medications (ASMs) as 20 seizures compared to those with
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy.
- Department of Epileptology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
- Epilepsy Center, Child Neuropsychiatry Unit, AAST Santi Paolo Carlo, Milan, Italy.
- Department of Health Sciences, Università degli Studi, Milan, Italy.
- IRCCS Neuromed, Pozzilli, Italy.
- Department of Human Neurosciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
ORCID-Profile: Simona Lattanzi, Laura Canafoglia, Giuseppe Didato, Giovanni Falcicchio, Chiara Pizzanelli, Carlo Di Bonaventura
Zitieren
APA
Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Cerulli Irelli, E., Chiesa, V., Dainese, F., De Maria, G., Didato, G., Di Gennaro, G., Falcicchio, G., Fanella, M., Ferlazzo, E., Gangitano, M., La Neve, A., Mecarelli, O., Montalenti, E., Morano, A., Piazza, F., …, & BRIVAFIRST (Brivaracetam Add‐On First Italian Network Study) Group Membership (2023). Adjunctive brivaracetam and sustained seizure frequency reduction in very active focal epilepsy. Epilepsia, 64(11), 2922-2933. https://doi.org/10.1111/epi.17740
Vancouver
Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Cerulli Irelli E, Chiesa V, et al. Adjunctive brivaracetam and sustained seizure frequency reduction in very active focal epilepsy. Epilepsia. 2023;64(11):2922-2933. doi:10.1111/epi.17740
BibTeX
@article{Lattanzi2023,
author = {Lattanzi, Simona and Canafoglia, Laura and Canevini, Maria Paola and Casciato, Sara and Cerulli Irelli, Emanuele and Chiesa, Valentina and Dainese, Filippo and De Maria, Giovanni and Didato, Giuseppe and Di Gennaro, Giancarlo and Falcicchio, Giovanni and Fanella, Martina and Ferlazzo, Edoardo and Gangitano, Massimo and La Neve, Angela and Mecarelli, Oriano and Montalenti, Elisa and Morano, Alessandra and Piazza, Federico and Pizzanelli, Chiara and Pulitano, Patrizia and Ranzato, Federica and Rosati, Eleonora and Tassi, Laura and Di Bonaventura, Carlo and BRIVAFIRST (Brivaracetam Add‐On First Italian Network Study) Group Membership, BRIVAFIRST (Brivaracetam Add‐On First Italian Network Study) Group Membership},
title = {Adjunctive brivaracetam and sustained seizure frequency reduction in very active focal epilepsy},
journal = {Epilepsia},
year = {2023},
volume = {64},
number = {11},
pages = {2922--2933},
doi = {10.1111/epi.17740}
}
EUVIMED